A 51-year-old male presented with nasal obstruction, followed by progressive hearing loss and blurred vision. Imaging identified space-occupying lesions in the paranasal sinuses, orbits, and paraspinal regions, while laboratory tests confirmed positive anti-proteinase 3 anti-neutrophil cytoplasmic antibody(PR3- ANCA) immunoglobulin G (IgG)and markedly elevated serum IgG4. Despite treatment with corticosteroids, immunosuppressants, and radiotherapy, the patient exhibited steroid dependency with relentless disease progression. Following multidisciplinary consultation, a diagnosis of inflammatory myofibroblastic tumor (IMT) coexisting with ANCA- associated vasculitis (AAV) was favored, though IgG4-related disease remained a critical differential. Ultimately, profound immunosuppression precipitated a severe herpesvirus infection, leading to disseminated intravascular coagulation and multiple organ dysfunction syndrome. This case underscores the rarity and diagnostic complexity of concurrent IMT and AAV, highlights the therapeutic dilemma of balancing primary disease control against fatal opportunistic infections, and emphasizes the critical role of multidisciplinary collaboration in the diagnosis and treatment of complex diseases.

OBJECTIVE To investigate the therapeutic effect and mechanism of Qiwei dongqingye powder （QDP） on bronchial asthma in mice. METHODS The mice were divided into blank group （normal saline）， model group （normal saline）， dexamethasone group （2 mg/kg）， and QDP low-， medium-， and high-dose groups （200， 400， 800 mg/kg）， with 14 mice in each group. Except for the blank group， mice in all other groups were given ovalbumin via intraperitoneal injection followed by aerosol inhalation to induce a bronchial asthma model. During the modeling process， mice in each group were administered corresponding drug solutions or normal saline intragastrically/intraperitoneally. After the last medication， the number of cells in the bronchoalveolar lavage fluid （BALF） of the mice was observed and counted； the pathological changes of the bronchus and lung tissue were observed； the levels of malondialdehyde （MDA）， nitric oxide （NO）， total superoxide dismutase （T-SOD）， and glutathione peroxidase （GSH-Px） in the lung tissue of the mice were determined， and the level of interleukin-17 （IL-17） in the BALF and serum was determined. Transcriptomics was employed to predict and validate the mechanism of action of QDP against bronchial asthma. RESULTS Compared with the model group， the total cell count， neutrophil count， lymphocyte count， and macrophage counts in the BALF of the QDP high-dose group were all significantly reduced （ P ＜0.05）； the levels of MDA and NO in the lung tissue， and the levels of IL-17 in the BALF and serum were all decreased significantly （ P ＜0.05）； the levels of T-SOD and GSH-Px were significantly increased （ P ＜0.05）； the arrangement of lung tissue cells tended to normalize， with reduced infiltration of inflammatory cells and decreased exfoliation of bronchial simple columnar epithelial cells. The transcriptomic results revealed that the differentially expressed genes were B-cell receptor signaling pathway， nuclear factor κB （NF-κB） signaling pathway， ferroptosis signaling pathway， and others. Further validation revealed that， compared with the model group， the expression levels of NF-κB p65 and chemokine ligand 20， as well as the phosphorylation level of NF-κB inhibitor protein α， were significantly decreased in the lung tissues of the mice in all QDP groups （ P ＜0.05）. Conversely， the protein expression of nuclear factor erythroid 2-related factor 2 （Nrf2） and heme oxygenase 1 （HO-1） were significantly increased （ P ＜0.05）. CONCLUSIONS QDP can effectively alleviate bronchial asthma by inhibiting the NF-κB signaling pathway， activating the Nrf2/HO-1 signaling pathway， regulating oxidative stress， and reducing inflammatory responses.

Objective To evaluate the association between paroxetine exposure and breast cancer risk by using a multi-omics approach and to elucidate the underlying molecular mechanisms. Methods A cross-sectional analysis was conducted using NHANES data from 2005 to 2016 to assess paroxetine exposure and breast cancer prevalence. Network pharmacology was employed to identify common targets and pathways, followed by Mendelian randomization analysis to validate causal relationships and molecular docking to further verify key interactions. Results Among 5520 participants, paroxetine users showed a 270% increased risk of breast cancer after multivariate adjustment (adjusted OR=3.70, 95%CI: 1.15-11.99, P=0.032). Network pharmacology identified 92 overlapping targets, with mTOR emerging as a central hub (IVW OR=1.09, 95%CI: 1.06-1.13, P=6.67×10⁻⁷). Molecular docking confirmed a high-affinity binding between paroxetine and mTOR (binding energy: −8.3 kcal/mol). Pathway enrichment analysis indicated that the PI3K-Akt signaling pathway, endocrine resistance, and chemical carcinogenesis were key mechanisms. Conclusion Paroxetine use may be linked to an increased risk of breast cancer, possibly mediated through the mTOR pathway.

With the rapid development of social economy and the continuous improvement of human living standard, the incidence, fatality and recurrence rates of cardiovascular disease (CVD) are increasing year by year, which seriously affects people's life and health. Conventional therapeutic drugs have limited improvement on the disability rate, so the search for new therapeutic drugs and action targets has become one of the hotspots of current research. In recent years, the therapeutic role of the natural compound rosmarinic acid (RA) in CVD has attracted much attention, which is capable of preventing CVD by modulating multiple signalling pathways and exerting physiological activities such as antioxidant, anti-apoptotic, anti-inflammatory, anti-platelet aggregation, as well as anti-coagulation and endothelial function protection. In this paper, the role of RA in the prevention of CVD is systematically sorted out, and its mechanism of action is summarised and analysed, with a view to providing a scientific basis and important support for the in-depth exploration of the prevention value of RA in CVD and its further development as a prevention drug.

[Objective]To summarize the academic experience of Professor FAN Yongsheng,one of the first national famous traditional Chinese medicine masters,in treating the damp-heat syndrome of rheumatism.[Methods]Through the follow-up study,collecting and organizing Professor FAN Yongsheng's clinical cases of damp-heat syndrome of rheumatism,combined with the relevant ancient books and literature,summarizing the academic experience of Professor FAN Yongsheng in the diagnosis and treatment of damp-heat syndrome of rheumatism by Sanjiao method,focusing on the theoretical origin of Sanjiao method,the division of upper,middle and lower Jiao,as well as the practice of the clinical evidence,and added with the evidence of the experimental cases for support.[Results]The term Sanjiao originated in Huangdi Neijing.ZHANG Zhongjing deepened the concept of the Qi transformation of Sanjiao.XUE Xue pioneered the syndrome differentiation of the Sanjiao framework in Treatise on Dampness and Heat.WU Jutong systematically established the Sanjiao syndrome differentiation system in Systematic Differentiation of Warm Diseases.Professor FAN Yongsheng believes that the etiology of rheumatism with damp-heat syndrome is mostly attributed to insufficient endowment,exogenous or endogenous damp-heat obstruction in the Sanjiao,which results in the evil of damp-heat disturbing the upper-Jiao,trapping in the middle-Jiao and injecting into the lower-Jiao.When treating the disease,the parts of the Sanjiao where the damp-heat is located should be recognized.The treatment according to Sanjiao should be applied respectively with"propagation and opening""clearing"and"osmosis",and at the same time,the overall situation should be taken into account,and the three methods are often used together to eliminate the damp-heat and facilitate the Sanjiao.Three clinical cases demonstrated significant efficacy:Case 1 involved damp-heat clouding the upper-Jiao,treated with heat-clearing,damp-resolving,lung-ventilating and cough-relieving methods;Case 2 featured with damp-heat lodging in the middle-Jiao,managed with heat-clearing,spleen-strengthening and liver-soothing therapies;Case 3 presented damp-heat diffusing to the lower-Jiao,addressed through heat-clearing,damp-draining and collateral-unblocking strategies.All cases achieved satisfactory clinical results.[Conclusion]Professor FAN Yongsheng's academic experience in treating damp-heat syndrome of rheumatism by flexibly utilizing the Sanjiao method,which is based on inheritance,provides a theoretical basis and practical paradigm for the clinical management of rheumatism with damp-heat syndrome and is worth promoting and applying in the clinic.

Objective:To design a set of simulation system for surgical operation based on virtual reality(VR)technique and intelligent scoring functions,so as to assess its clinical application effect.Methods:The Digital Imaging and Communications in Medicine(DICOM)images of typical patients were collected.Materialise Interactive Medical Image Control System(MIMICS)software was adopted to reconstruct the three-dimensional(3D)model of diseased organs.Surgical instrument models were constructed by using 3D Max software.Unity 3D software was adopted to construct simulation system for surgical operation with VR+intelligent scoring.A total of 40 surgical resident physicians,who were employed with 3 years since 2019 in The Second Affiliated Hospital of Kunming Medical University,were selected.They were divided into observation group and control group,with 20 cases in each group.The observation group used simulation system for surgical operation to conduct intelligent scoring for cholecystectomy under laparoscope,and the control group used conventional scoring for surgical operation.The scores of surgical operation and test between the two groups were compared.Results:The mean value of surgical operation time of the observation group was(1.72±0.41)h,and the average incidence of complication was(0.03±0.02)%,both of them of the observation group were significantly lower than those of the control group[(2.25±0.42)h and(0.05±0.03)%].The differences of them between two groups were statistically significant(t=9.00,4.08,P<0.05).The test scores of surgical operation of the observation group was also significantly higher than that of the control group(t=5.26,P<0.001).Conclusion:The developed simulation system for surgical operation with VR+intelligent scoring can significantly enhance users'surgical operation skills and improve learning outcomes,which has favorable prospects in future applications.

Objective To observe the clinical efficacy of Taohong Tongluo Granules in the intervention of patients with angina pectoris of qi stagnation and blood stasis syndrome after percutaneous coronary intervention(PCI)and evaluate quality of life of patients.Methods A total of 92 patients with angina pectoris of qi stagnation and blood stasis syndrome after PCI for coronary heart disease were enrolled and divided into the experimental group and the control group according to random number table method,with 46 cases in each group.Both groups received conventional Western medicine treatment.The experimental group received Taohong Tongluo Granules,and the control group was given placebo,1 bag each time,twice a day,orally,for 12 weeks continuously.The angina pectoris symptom scores,the effective rate of angina pectoris treatment,TCM syndrome scores,inflammatory indexes(hs-CRP,IL-1β,IL-18),lipid metabolism indexes(TG,TC,LDL-C,HDL-C),and anxiety scores of the two groups before and after treatment were observed.In addition,the safety of Taohong Tongluo Granules was evaluated.Results During the study,2 cases in the experimental group were lost to follow-up,1 case in the control group was eliminated and 1 case was lost to follow-up.The total effective rate was 88.63%(39/44)in the experimental group and 47.72%(21/44)in the control group,and the experimental group was better than the control group(P<0.01).After treatment,the angina symptom score and TCM syndrome score in the experimental group decreased,and were lower than those in the control group(P<0.05).After treatment,the levels of inflammatory indexes(hs-CRP,IL-1β,IL-18)in the experimental group decreased,and were significantly lower than those in the control group(P<0.05);the levels of blood lipid metabolism indexes(TG,TC,LDL-C,HDL-C)in the experimental group were improved,and were significantly better than those in the control group(P<0.05).The anxiety state of the experimental group was significantly improved after treatment,and the effect was significantly better than that of the control group(P<0.05).During the test,no adverse reactions such as dizziness,nausea,abdominal pain and diarrhea occurred in the two groups,and the safety was good.Conclusion Taohong Tongluo Granules can significantly improve the symptoms of angina pectoris and TCM syndromes in patients with angina pectoris of qi stagnation and blood stasis syndrome after PCI,and reduce the anxiety state of patients,relieve the anxiety state of patients,reduce the inflammatory-related indexes such as hs-CRP,IL-1β and IL-18,further improve lipid metabolism,and ultimately improve the quality of life of patients.

The prevalence of rheumatic diseases among elderly patients is on the rise.These patients often exhibit frailty, which is significantly associated with an increased risk of falls, disability, hospitalization, and mortality.In this review, we discussed the concept of frailty, its pathogenesis, and the assessment tools available for evaluating it, as well as the relationship between frailty and rheumatic diseases in elderly patients.Our aim is to enhance the understanding of frailty, promote effective management of rheumatic diseases, and reduce the incidence of adverse events.

Objective:To analyze the utilization of pre-exposure prophylaxis (PrEP) service against HIV and related factors in young men who have sex with men (MSM) in Hangzhou.Methods:A cross-sectional study design was used in this questionnaire survey in young MSM recurited through local MSM social organization in Hangzhou from September 2022 to March 2023. The estimated sample size was 242. The information about the social-demographic characteristics, behavioral characteristics, utilization of the post exposure prophylaxis (PEP) service, awareness and utilization of PrEP service of the young MSM were collected. Logistic regression model was used to analyze the related factors of the PrEP utilization.Results:A total of 273 young MSM aged 16- 24 years were surveyed in the study. A total for 20.1% (55/273) of them had used PrEP service. Multivariate logistic regression analysis showed that the factors related to PrEP service utilization included age 16-20 years (a OR=3.03, 95% CI:1.12-8.20), education level of senior high school or below (a OR=2.83, 95% CI:1.09-7.35), full-time/part-time work (a OR=3.25, 95% CI: 1.26-8.38), homosexual activity in the past 6 months (a OR=6.71, 95% CI:1.84-24.55), inquiring medical staff about PrEP (a OR=4.71, 95% CI:1.99-11.13) and PEP service use (a OR=6.09, 95% CI:2.69-13.81). Conclusions:The utilization rate of PrEP service was low in young MSM in Hangzhou. It is necessary to strengthen the health education about PrEP and improve the undertanding of PrEP and service capability of medical staff to promote the utilization of PrEP service in young MSM.

Objective To analyze the efficacy and safety of ustekinumab(UST)in patients with moderate-to-severe Crohn's disease(CD),and to identify factors influencing clinical outcomes.Methods Data were retrospectively collected from patients with moderate-to-severe CD treated with UST in the First Affiliated Hospital of Zhejiang Chinese Medical University and Hangzhou Hospital of Traditional Chinese Medicine between November 2020 and May 2023.Patients were categorized into first-line(not treated with biologic agents,n=68)and second-line(treated with biologic agents,n=66)treatment groups based on prior use of biologic agents.Baseline characteristics,including age,sex,smoking status,disease duration,age at diagnosis,lesion site,disease behavior,perianal disease,history of intestinal surgery,and CD-related drug use,were compared between the two groups.Crohn's disease activity indices(CDAI)were recorded at baseline,week 14,and week 52 to assess the clinical efficacy at weeks 14 and 52.Endoscopic evaluations were performed at baseline and week 52 to evaluate endoscopic efficacy at week 52.The 52-week drug persistence rate and safety profile were also analyzed.Influencing factors related to clinical outcomes were evaluated using univariate and multivariate logistic regression.Results A total of 134 patients with moderate-to-severe CD treated with UST were included.At week 14,clinical response and remission rates were 75.4%(101/134)and 33.6%(45/134),respectively,with no significant difference in clinical efficacy between first-line and second-line groups(clinical response rate:77.9%vs.72.7%,P=0.484;clinical remission rate:38.2%vs.28.8%,P=0.247).At week 52,clinical response and remission rates were 79.9%(107/134)and 56.0%(75/134),respectively.The rates of endoscopic response and remission were 70.9%(95/134)and 38.8%(52/134),respectively.There were no significant differences in clinical efficacy(clinical response rate:80.9%vs.78.8%,P=0.763;clinical remission rate:60.3%vs.51.5%,P=0.306)and endoscopic efficacy(endoscopic response rate:76.5%vs.65.2%,P=0.149;endoscopic remission rate:42.6%vs.34.8%,P=0.354)between the two groups.The 52-week drug persistence rate was 85.8%(115/134),and the adverse reaction rate was 4.5%(6/134).Compared with first-line treatment group,biologic-experienced patients had a significantly higher proportion of dose-optimized therapy in second-line treatment group(45.5%vs.22.1%,P=0.004).Multivariate logistic regression showed that the 14-week clinical response was a significant predictor of 52-week clinical remission,while perianal disease and intestinal surgery history were significant factors associated with treatment failure(P<0.05).Conclusions UST demonstrates significant efficacy in improving clinical and endoscopic outcomes for moderate-to-severe CD patients,with a favorable safety profile.Clinical response at 14 weeks is strongly predictive of clinical remission at 52 weeks.Patients with perianal disease or a history of intestinal surgery were at higher risk of treatment failure.